May 21, 2002
Dear Dr. Little: I was diagnosed HIV+ in 1995, am treatment naive, and have been in good health since then. My CD4 count is 594 and viral load is 3,849. Here's my question; I've been invited to participate in a clinical trial at a major research hospital in which I will be given AZT monotherapy in directly observed therapy for 21 days and I am interested in your opinion as to the possible future consequences this might cause to my immune system and possible cross resistance to other HAART meds. The goal of the study is to evaluate the lowest effective dose of AZT. After the 21 day period the AZT would be discontinued. I'd like to participate for two reasons; it seems it might help others and I could use the money! Thanks very much.
Response from Dr. Little
I think that the risk is low (not zero) that a 21 day course of AZT would result in drug resistance. If you have never received any antiretroviral drug therapy, the risk is actually quite low. The problem is only that I cannot say the risk is zero. This means that you need to balance the personal benefit with the personal risk and make sure the risk is justified for you.
Total resistance equals total frustration
- Groin Pain Sign Of HIV Infection
- Can HIV Be Transmitted Through Sex With A Prostitute?
- How Likely Is It To Get AIDS From Sex With A Prostitute?
- Fever After Unprotected Sex Without Ejaculation Worried I Have HIV
- Itchy Skin After Kissing Cold Sore Sign Of HIV AIDS
- Night Sweats After Receptive Anal Sex With Condom What Are The Chances Of HIV
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.